Story · Medicine & Biotech

Belzutifan Plus Lenvatinib Moves Closer to EU Approval for Advanced Kidney Cancer

1 outlet · first reported by OncoDaily on

A new combination treatment for advanced kidney cancer has moved one step closer to European approval. Merck has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for (OncoDaily)

Coverage, in order

  1. OncoDaily obscure study
    Belzutifan Plus Lenvatinib Moves Closer to EU Approval for Advanced Kidney Cancer

    A new combination treatment for advanced kidney cancer has moved one step closer to European approval. Merck has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.